Production (Stage)
Akebia Therapeutics, Inc.
AKBA
$2.86
$0.031.06%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -5.30% | -33.67% | 21.53% | 58.82% | 26.66% |
| Total Depreciation and Amortization | -21.93% | -0.34% | 11.00% | 11.04% | 10.97% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 271.59% | 260.08% | 140.92% | 133.54% | 138.96% |
| Change in Net Operating Assets | -65.93% | -91.42% | -430.86% | -194.30% | -26.30% |
| Cash from Operations | -37.72% | -73.88% | 49.18% | -12.05% | 63.40% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | -- | -- | -- |
| Total Debt Issued | -51.35% | -- | -- | -- | -- |
| Total Debt Repaid | 98.42% | -15.93% | -87.92% | 20.88% | -7.60% |
| Issuance of Common Stock | 248.29% | 533.41% | 32,542.86% | 26,420.62% | 26,406.19% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 22.00% | -- | -- | -- | -- |
| Cash from Financing | 1,049.21% | 297.03% | 208.91% | 143.71% | 118.88% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 545.28% | 118.46% | 87.47% | 84.59% | 86.40% |